HORMONE REPLACEMENT THERAPY WITH ALENDRONATE IN POST MEN

Project: Research project

Description

The purpose of this contract is to conduct a randomized, double-blind, controlled trial of a combination of low-dose, continuous hormone replacement (o.d mg/day conjugated equine estrogens, +2.5 mg/day medroxyrpogesterone) with alendronate (10mg/day). The two drugs will each be tested alone and in combination in estrogen deprived, osteopenic, postmenopausal women over 60 years of age. Each of the three groups will enroll 72 participants and follow them for three years. Calcium and Vitamin D supplements will be given to all participants throughout the study. The hypothesis that will be tested is that the combined therapy shows a greater bone effect than either drug given alone. The primary outcome measures will be spine bone mineral density, total hip bone mineral density, and total body bone mineral content.
StatusFinished
Effective start/end date9/30/999/29/04

Funding

  • National Institutes of Health
  • National Institutes of Health: $422,363.00

Fingerprint

Alendronate
Hormone Replacement Therapy
Bone Density
Pelvic Bones
Conjugated (USP) Estrogens
Contracts
Vitamin D
Pharmaceutical Preparations
Estrogens
Spine
Outcome Assessment (Health Care)
Hormones
Calcium
Bone and Bones
Therapeutics